Cargando…

Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review

Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare and distinct subtype of non-small-cell lung carcinoma associated with Epstein–Barr virus (EBV) infection. We systematically reviewed the recent research that expands our knowledge about PLELC, with main focus on its genetic profile, tumor-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yan, Ren, Siying, Liu, Yukang, Han, Wei, Liu, Wenliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227818/
https://www.ncbi.nlm.nih.gov/pubmed/32494151
http://dx.doi.org/10.2147/OTT.S241337
_version_ 1783534563641786368
author Hu, Yan
Ren, Siying
Liu, Yukang
Han, Wei
Liu, Wenliang
author_facet Hu, Yan
Ren, Siying
Liu, Yukang
Han, Wei
Liu, Wenliang
author_sort Hu, Yan
collection PubMed
description Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare and distinct subtype of non-small-cell lung carcinoma associated with Epstein–Barr virus (EBV) infection. We systematically reviewed the recent research that expands our knowledge about PLELC, with main focus on its genetic profile, tumor-infiltrating environment, PD-L1 expression, circulating EBV-DNA, clinical utility of 18F-FDG PET/CT, and treatment strategy. A low frequency of typical driver mutations and widespread existence of copy number variations was detected in PLELC. Persistent EBV infection may trigger intense infiltration of lymphocytes, representing enhanced tumor immunity and possibly resulting in a better prognosis. Circulating EBV-DNA in the plasma of patients with PLELC may predict disease progression and response to therapy. PLELC is 18F-FDG avid, and 18F-FDG PET may help refine palliation strategies and subsequently improve the prognosis. Most of the reported patients present at early and resectable stage, and surgical resection with curative intent is the preferred approach. There is currently no consensus on the regimen of chemotherapy for patients with advanced stages. EGFR-targeted therapies seem to have no therapeutic effect, and the clinical impact of PD-1/PD-L1 therapy is uncertain but worthy of further research.
format Online
Article
Text
id pubmed-7227818
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72278182020-06-02 Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review Hu, Yan Ren, Siying Liu, Yukang Han, Wei Liu, Wenliang Onco Targets Ther Review Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare and distinct subtype of non-small-cell lung carcinoma associated with Epstein–Barr virus (EBV) infection. We systematically reviewed the recent research that expands our knowledge about PLELC, with main focus on its genetic profile, tumor-infiltrating environment, PD-L1 expression, circulating EBV-DNA, clinical utility of 18F-FDG PET/CT, and treatment strategy. A low frequency of typical driver mutations and widespread existence of copy number variations was detected in PLELC. Persistent EBV infection may trigger intense infiltration of lymphocytes, representing enhanced tumor immunity and possibly resulting in a better prognosis. Circulating EBV-DNA in the plasma of patients with PLELC may predict disease progression and response to therapy. PLELC is 18F-FDG avid, and 18F-FDG PET may help refine palliation strategies and subsequently improve the prognosis. Most of the reported patients present at early and resectable stage, and surgical resection with curative intent is the preferred approach. There is currently no consensus on the regimen of chemotherapy for patients with advanced stages. EGFR-targeted therapies seem to have no therapeutic effect, and the clinical impact of PD-1/PD-L1 therapy is uncertain but worthy of further research. Dove 2020-05-11 /pmc/articles/PMC7227818/ /pubmed/32494151 http://dx.doi.org/10.2147/OTT.S241337 Text en © 2020 Hu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Hu, Yan
Ren, Siying
Liu, Yukang
Han, Wei
Liu, Wenliang
Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review
title Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review
title_full Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review
title_fullStr Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review
title_full_unstemmed Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review
title_short Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review
title_sort pulmonary lymphoepithelioma-like carcinoma: a mini-review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227818/
https://www.ncbi.nlm.nih.gov/pubmed/32494151
http://dx.doi.org/10.2147/OTT.S241337
work_keys_str_mv AT huyan pulmonarylymphoepitheliomalikecarcinomaaminireview
AT rensiying pulmonarylymphoepitheliomalikecarcinomaaminireview
AT liuyukang pulmonarylymphoepitheliomalikecarcinomaaminireview
AT hanwei pulmonarylymphoepitheliomalikecarcinomaaminireview
AT liuwenliang pulmonarylymphoepitheliomalikecarcinomaaminireview